{"disease":{"id":"renal-cell-cancer-metastatic","name":"renal cell cancer metastatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT04623502","title":"An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06726421","title":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT07227415","title":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03829501","title":"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":222,"lead_sponsor_name":"Kymab Limited","has_results":true},{"nct_id":"NCT07354282","title":"Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Spanish Oncology Genito-Urinary Group","has_results":false},{"nct_id":"NCT07240610","title":"Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":145,"lead_sponsor_name":"Zhe Chen","has_results":false},{"nct_id":"NCT05119335","title":"A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03983954","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NeoTX Therapeutics Ltd.","has_results":false},{"nct_id":"NCT03634540","title":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT03454451","title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Corvus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03682289","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT06648902","title":"Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Kidney Cancer Research Bureau","has_results":false},{"nct_id":"NCT07292168","title":"A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"Kidney Cancer Research Bureau","has_results":false},{"nct_id":"NCT06010875","title":"A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT00670748","title":"Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":45,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05092373","title":"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07197580","title":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Telix Pharmaceuticals (Innovations) Pty Limited","has_results":false},{"nct_id":"NCT04749602","title":"Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Kidney Cancer Research Bureau","has_results":false},{"nct_id":"NCT02978404","title":"Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT04834778","title":"A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"HiberCell, Inc.","has_results":false},{"nct_id":"NCT07043608","title":"Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Kelly Fitzgerald, MD","has_results":false},{"nct_id":"NCT05935748","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03876925","title":"A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06264479","title":"Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2","phase":"","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Ourotech, Inc.","has_results":false},{"nct_id":"NCT04368546","title":"Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)","phase":"","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT03260504","title":"Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Washington","has_results":true}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}